Amarin Corp Plc (AMRN)

[Notademoc]

Author(s)/Faculty: Christie M. Ballantyne, MD; Deepak L. Bhatt, MD, MPH; Yehuda Handelsman, MD, FACP, FNLA, MACE
Source: Healio Education Lab - Cardiology
Type: Lecture Articles/Items: 5
Release Date: 9/11/2018 Expiration Date: 9/10/2019
Credit Type: CME / ABIM MOC Number of Credits: 1
Cost: Free Provider: Vindico Medical Education
There is an association between atherosclerotic cardiovascular disease and low-density lipoprotein cholesterol as well as triglyceride levels in both type 1 and type 2 diabetes. The risk of coronary heart disease (CHD) is greater at any given level of serum cholesterol in patients with diabetes, and its association with hypertriglyceridemia is stronger than in the general population. Diabetic dyslipidemia can be partly corrected by insulin treatment and improved blood glucose control. Importantly, there is strong and convincing evidence that cholesterol-lowering therapy significantly reduces CHD in patients with diabetes. Statin therapy may need to be supplemented with proprotein convertase subtilsin-kexin type 9 (PCSK9) inhibitors to lower cholesterol levels adequately. In this educational activity, expert physicians will discuss the pathogenesis of diabetic dyslipidemia and the latest clinical information on PCSK9 inhibitors.